Log in

TSE:TRILTrillium Therapeutics Stock Price, Forecast & News

C$10.04
-0.58 (-5.46 %)
(As of 06/4/2020 01:37 AM ET)
Add
Compare
Today's Range
C$9.81
Now: C$10.04
C$10.74
50-Day Range
C$6.02
MA: C$7.82
C$10.62
52-Week Range
C$0.30
Now: C$10.04
C$11.37
Volume168,380 shs
Average Volume357,735 shs
Market CapitalizationC$837.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-416-5950627

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$124,000.00
Cash FlowC$0.30 per share
Book ValueC($0.86) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$837.71 million
Next Earnings DateN/A
OptionableOptionable

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.

Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions

How has Trillium Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Trillium Therapeutics' stock was trading at C$7.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 42.8% and is now trading at C$10.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Trillium Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Trillium Therapeutics.

Has Trillium Therapeutics been receiving favorable news coverage?

Media coverage about TRIL stock has been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trillium Therapeutics earned a news sentiment score of -3.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutTrillium Therapeutics.

Who are some of Trillium Therapeutics' key competitors?

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Canada Goose (GOOS), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Novavax (NVAX), Adverum Biotechnologies (ADVM), Advanced Micro Devices (AMD), BioNano Genomics (BNGO), Canadian Natural Resources (CNQ) and Pfizer (PFE).

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:
  • Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & Director
  • Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)
  • Dr. Robert Uger, Chief Scientific Officer
  • Dr. Penka Petrova, Chief Devel. Officer
  • Dr. Yaping Shou, Chief Medical Officer

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

How do I buy shares of Trillium Therapeutics?

Shares of TRIL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately C$10.04.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of C$837.71 million and generates C$124,000.00 in revenue each year.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.